Do mAbs and paraprotein affect COVID-19 Serological Testing in Patients with Multiple Myeloma?

  Dec 04 2020 Tagged mAbs, MM, COVID-19

Adults 13

SARS-CoV-2 (COVID-19) serology tests do not appear to interfere or cause cross-reactivity with therapeutic monoclonal antibody (t-mAb) treatments for hematologic malignancies (HM) such as multiple myeloma (MM), according to a study published in Diagnostics.

“Alarming results from China and the U.K. confirm the vulnerability of [patients with] HM to (COVID-19)... Given that the immunoassay interference from the endogenous monoclonal immunoglobulin (M paraprotein) and treatment antibodies continually challenges the MM management, it is critical to evaluate the SARS-CoV-2 serology tests for suspected interference/cross-reactivity.”

Read the full article.

Visit website
Last Updated on Monday 14 December 2020.